Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 75 HER2-positive Breast Cancer 10 Neoplasms 8 Neoplasm Metastasis 4 Colonic Neoplasms 4 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Prostatic Neoplasms 3 Multiple Myeloma 3 Hematologic Neoplasms 3 Endometrial Neoplasms 3 Brain Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Urinary Bladder Neoplasms 2 Salivary Gland Neoplasms 2 Rectal Neoplasms 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Inflammatory Breast Neoplasms 2 HER2-positive Early Breast Cancer 2 Colorectal Neoplasms 2 Breast Diseases 2 Biliary Tract Neoplasms 2 Anatomic Stage II Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × pertuzumab × 1 year × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡